Conejos-Sanchez, I.; Gallon, E.; Nino-Pariente, A.; Smith, J. A.; De la Fuente, A. G.; Di Canio, L.; Pluchino, S.; Franklin, R. J. M.; Vicent, M. J. published the artcile< Polyornithine-based polyplexes to boost effective gene silencing in CNS disorders>, Related Products of 2127-03-9, the main research area is polyornithine siRNA polyplex central nervous system disorder.
Gene silencing therapies have successfully suppressed the translation of target proteins, a strategy that holds great promise for the treatment of central nervous system (CNS) disorders. Advances in the current knowledge on multimol. delivery vehicles are concentrated on overcoming the difficulties in delivery of small interfering (si)RNA to target tissues, which include anatomical accessibility, slow diffusion, safety concerns, and the requirement for specific cell uptake within the unique environment of the CNS. The present work addressed these challenges through the implementation of polyornithine derivatives in the construction of polyplexes used as non-viral siRNA delivery vectors. Physicochem. and biol. characterization revealed biodegradability and biocompatibility of our polyornithine-based system and the ability to silence gene expression in primary oligodendrocyte progenitor cells (OPCs) effectively. In summary, the well-defined properties and neurol. compatibility of this polypeptide-based platform highlight its potential utility in the treatment of CNS disorders.
Nanoscale published new progress about Biocompatibility. 2127-03-9 belongs to class pyridine-derivatives, and the molecular formula is C10H8N2S2, Related Products of 2127-03-9.